内皮抑素抗黑色素瘤血管新生时间窗及最佳剂量的研究

目的:获取不同黑色素瘤发展阶段的荷瘤鼠的最佳治疗时间以及最佳用药量。方法:将肿瘤大小不等的雄性黑色素瘤荷瘤鼠进行内皮抑素分组对比治疗, 在用药3、5、7天后处死荷瘤鼠, 剥离瘤体, 称瘤重, 分析生长趋势, 做病理切片并进行HE染色和免疫组化。在与对照组进行对照后, 根据肿瘤的大小、恶性化的程度以及CD31和VEGF的表达情况, 找出内皮抑素的用药最有效的治疗时间窗。然后通过进一步实验, 在已经检测出的不同肿瘤大小的荷瘤鼠的恩度作用时间窗内, 给荷瘤鼠使用用不同浓度梯度的药物, 在不同肿瘤发展大小之后剥离瘤体, 做与上述类似的操作并分析, 确定在治疗时间窗时的恩度使用的最佳剂量。结论:5天为内皮抑素抗黑色素瘤血管新生时间窗, 两个实验组中, 中等剂量即15 mg/kg和20 mg/kg为恩度作用最佳剂量。

Abstract

Objective: To get the exact appropriate time window and optimum medicine quantity in mice bearing melanoma treatment. Methods: Male mice bearing melanoma with different diameter were injected with endostatin for treatment, and were sacrificed separately 3, 5, 7 days after endostatin was applied. Then tumors were peeled, weighted, analyzed with growth trend and the pathological sections of the peeled tumors were analyzed by immunohistochemistry and HE staining. Compared with the control group, an appropriate time window for treatment would be determined with the size, grade of the tumors and expression of CD31 and VEGF considered. Next, under the condition of the known ideal window time, tumor-bearing mice were injected with endostatin at different concentrations. Similarly, an appropriate drug concentration would be found.Conclusion: The time 5 days after endostatin was applied was the exact appropriate time window in mice bearing melanoma treatment. And moderate doses,15mg/kg and 20mg/kg were the optimum endostatin quantities in this experiment.

参考文献

[1] 曹瑞华, 廖万清. 内皮抑素与恶性黑素瘤治疗［J］.实用医药杂志, 2009, 26(1):65-67.

CAO Ruihua, LIAO Wanqing. Endostatin and the treatment of malignant melanoma［J］.Practical Journal of Medicine & Pharmacy, 2009, 26(1):65-67.

[2] 徐毅, 周建大, 罗成群, 等. 中国汉族人黑色素瘤家系临床特点分析［J］. 激光生物学报, 2007, 06:792-794.

XU Yi, ZHOU Jianda, LUO Chengqun, et al. Clinical characteristic of malignant melanoma of Chinese race people in China［J］. Acta Laser Biology Sinica, 2007, 06:792-794.

[3] KIM K S, KIM D S, CHUNG K H, et al. Inhibition of angiogenesis and tumor progression by hydrodynamic cotransfection of angiostatin K1-3, endostatin, and saxatilin genes［J］. Cancer Gene Therapy, 2006, 13(6):563-571.

[4] 周建大, 李文波, 罗成群, 等. 内皮抑素基因抗黑色素瘤细胞高转移的动物研究［J］. 激光生物学报, 2009, 04:435-439+430.

ZHOU Jianda, LI Wenbo, LUO Chengqun, et al. Zooscopy of endostain gene resistant to the highly metastatic capability of melanoma cells［J］.Acta Laser Biology Sinica, 2009, 04:435-439+430.

[5] REGULIER E, PAUL S, MARIGLIANO M, et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach［J］. Cancer Gene Therapy, 2001, 8(1):45-54.

[6] 肖国宏, 罗成群, 唐国茂, 等. 人内皮抑素基因转染原代成人黑色素瘤细胞［J］.中南大学学报(医学版), 2005, 06:677-681.

XIAO Guohong, LUO Chengqun, TANG Guomao, et al. Human endostatin gene transfected adult skin melanoma cells［J］. Journal of Central South University(Medical Sciences), 2005, 06:677-681.

[7] ABDOLLAHI A, HAHNFELDT P, MAERCKER C, et al. Endostatin’s antiangiogenic signaling network.［J］. Molecular Cell, 2004, 13(5):649-663.

[8] DHANABAL M, RAMCHANDRAN R, WATERMAN M J, et al. Endostatin induces endothelial cell apoptosis［J］. Journal of Biological Chemistry, 1999, 274(17):11721-11726.

[9] DHANABAL M, VOLK R, RAMCHANDRAN R, et al. Cloning, expression, and in vitro activity of human endostatin.［J］. Biochemical & Biophysical Research Communications, 1999, 258(2):345-352.

[10] REHN M, VEIKKOLA T, KUKKVALDRE E, et al. Interaction of endostatin with integrins implicated in angiogenesis［J］. Proceedings of the National Academy of Sciences, 2001, 98(3):1024-1029.

[11] MACDONALD N J, SHIVERS W Y, NARUM D L, et al. Endostatin binds tropomyosin a potential modulator of the antitumor activity of endostatin［J］. Journal of Biological Chemistry, 2001, 276(27):25190-25196.

[12] KIM Y M, JANG J W, LEE O H, et al．Endostatin inhabits endothelial and tumor cellar invasion by blocking the activation and catalytic activity of matrix metal-oproteinase［J］.Cancer Res, 2000, 60(19): 5410-5413．

[13] ELLIS L M, HICKLIN D J. VEGF-targeted therapy: mechanisms of anti-tumour activity.［J］. Nature Reviews Cancer, 2008, 8(8):579.

[14] FOLKMAN J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action ［J］. Experimental Cell Research, 2006, 312(5):594-607.

[15] WINDER T, LENZ H. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer［J］. Gastroenterology, 2010, 138(6):2163-2176.

[16] 王慧娟, 张国伟, 王启鸣, 等. 吉非替尼耐药的晚期非小细胞肺癌联合重组人血管内皮抑素解救治疗的临床研究［J］. 实用临床医药杂志, 2012, 16(21):16-18.

WANG Huijuan, ZHANG Guowei, WANg Qiming, et al. Clinical study on the relief treatment of the combined recombinant human endostatin after failed treatment of gefitinib for advanced non-small cell lung cancer［J］. J Clin Med Prac, 2012, 16(21):16-18.

[17] 彭芳, 王谨, 邹毅, 等．重组内皮抑素对肿瘤血管结构和乏氧改善作用的实验观察［J］.中华放射肿瘤学杂志, 2011, 20(1):69-72.

PENG Fang, WANG Jin, ZOU Yi, et al. Recombinant human endostatin improves tumor vasculature and alleviates hypoxia in Lewis lung carcinoma［J］. Chin J Radiat Oncol, 2011, 20(1):69-72.

[18] 魏萍, 化疗对晚期NSCLC患者血清VEGF和内皮抑素的影响及临床意义［D］.山东大学, 2012.

WEI Ping, The clinical significance of the changes of serum VEGF and endostatin in patients with advanced non-small cell lung cancer treated by chemotherapy［D］. Shandong University, 2012.

刘伟琳, 颜宇, 李晶晶, 胡丰, 熊武, 唐瑞, 罗美, 周航, 周建大. 内皮抑素抗黑色素瘤血管新生时间窗及最佳剂量的研究[J]. 激光生物学报, 2017, 26(1): 50. LIU Weilin, YAN Yu, LI Jingjing, HU Feng, XIONG Wu, TANG Rui, LUO Mei, ZHOU Hang, ZHOU Jianda. Time Window and Optimum Quantity of Endostatin in Melanoma Angiogenesis Treatment[J]. Acta Laser Biology Sinica, 2017, 26(1): 50.

内皮抑素抗黑色素瘤血管新生时间窗及最佳剂量的研究

关于本站 Cookie 的使用提示

全站搜索

内皮抑素抗黑色素瘤血管新生时间窗及最佳剂量的研究

相关论文

相关资讯

关于本站 Cookie 的使用提示

全站搜索